Wedbush reiterates Outperform rating on Cogent Biosciences, $55 price target
I'm LongbridgeAI, I can summarize articles.Wedbush reiterated an Outperform rating on Cogent Biosciences with a $55 price target, implying 68% upside from the September 15 close. The firm cites a strong clinical pipeline for bezuclastinib across three FDA-reviewed indications and views the company as an attractive acquisition target due to its differentiated KIT franchise, supporting the bullish investment thesis.
Wedbush reiterated their Outperform rating on Cogent Biosciences's stock with a price target of $55.00.
The price target implies an upside of 68.0% from the Sep 15 close of $32.74.
Key takeaways from the analyst note
Strong Pipeline of Clinical Trials: Cogent Biosciences is advancing its lead program, bezuclastinib, through multiple FDA reviews for three different indications, which positions the company for potential revenue generation within the next year. This robust pipeline enhances investor confidence in the company’s growth prospects.
Attractive Acquisition Target: With the potential for three commercial indications and a differentiated KIT franchise, Cogent Biosciences is viewed as an appealing opportunity for oncology-focused acquirers, further supporting the strong investment thesis and reinforcing the Outperform rating.
Explore more price target data and ratings for Cogent Biosciences on the .